BMY vs PFE Comparison: AI Score, Valuation, Performance and Upside
Compare Bristol-Myers Squibb's newer-drug-launch pipeline against Pfizer's diversified but slower-growing post-pandemic portfolio.
Use this Bristol-Myers Squibb vs Pfizer comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
BMY holds the edge across 3 of 5 key metrics in this comparison. BMY has delivered stronger 1-year price return (+36.16% vs +14.93%), though PFE has the better forward P/E setup (9.83x vs 10.15x for BMY). BMY leads on both revenue growth (5.70%) and operating margin (34.42%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: -0.56% for BMY and +0.55% for PFE.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | BMY | PFE |
|---|---|---|
| AI scorei | 40.5 | 39.3 |
| AI ranki | #1136 | #1256 |
| Latest closei | $62.84 | $27.64 |
| 1M returni | -4.86% | +1.43% |
| 6M returni | +8.14% | +0.84% |
| 1Y returni | +36.16% | +14.93% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BMY | PFE |
|---|---|---|
| 1Y ago | $13.78K (+37.8%) started 2025-09-18 | $11.45K (+14.5%) started 2025-09-18 |
| 5Y ago | $14.02K (+40.2%) started 2021-09-20 | $9.11K (-8.9%) started 2021-09-20 |
| 10Y ago | $21.45K (+114.5%) started 2016-09-19 | $19.55K (+95.5%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | BMY | PFE |
|---|---|---|
| Market capi | $136B | $162.16B |
| Trailing P/Ei | 14.67 | 37.43 |
| Forward P/Ei | 10.15 | 9.83 |
| Price/Salesi | 2.07 | 2.13 |
| EV/Revenuei | 3.46 | 3.36 |
| Analyst targeti | $66.21 | $28.61 |
| Target upsidei | -0.56% | +0.55% |
| Metric | BMY | PFE |
|---|---|---|
| Revenue growthi | 5.70% | 2.60% |
| Earnings growthi | 153.10% | -10.10% |
| EPS growthi | +153.10% | -10.10% |
| FCF margini | +16.50% | +19.60% |
| Operating margini | 34.42% | 27.88% |
| Profit margini | 18.87% | 6.80% |
| ROIC proxyi | 46.60% | 5.01% |
| Return on equityi | 46.60% | 5.01% |
| Dividend yieldi | 3.76% | 6.05% |
| Payout ratioi | 55.29% | 226.32% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.23 | 0.30 |
| Debt/equityi | 201.86 | 74.25 |
| Current ratioi | 1.53 | 1.27 |
| Quick ratioi | 1.29 | 0.85 |
Over the past year, BMY and PFE have moved moderately in the same direction (correlation of 0.57), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BMY | PFE |
|---|---|---|---|
| 1Y | Growthi | +37.81% | +14.45% |
| CAGRi | +37.87% | +14.47% | |
| Volatilityi | 27.50% | 23.60% | |
| Sharpe ratioi | 1.14 | 0.50 | |
| Sortino ratioi | 1.83 | 0.78 | |
| Max drawdowni | 13.42% | 17.09% | |
| Current drawdowni | 7.71% | 4.76% | |
| Avg drawdowni | 4.34% | 6.72% | |
| Ulcer Indexi | 5.50% | 7.92% | |
| Max daily dropi | 4.07% | 3.43% | |
| Max wkly dropi | 7.58% | 9.46% | |
| 5Y | Growthi | +20.05% | -25.16% |
| CAGRi | +3.73% | -5.64% | |
| Volatilityi | 24.64% | 25.40% | |
| Sharpe ratioi | 0.09 | -0.28 | |
| Sortino ratioi | 0.13 | -0.41 | |
| Max drawdowni | 47.67% | 58.96% | |
| Current drawdowni | 13.87% | 46.46% | |
| Avg drawdowni | 21.01% | 38.14% | |
| Ulcer Indexi | 24.82% | 41.46% | |
| Max daily dropi | 8.51% | 6.72% | |
| Max wkly dropi | 11.78% | 11.19% | |
| 10Y | Growthi | +52.83% | +25.27% |
| CAGRi | +4.33% | +2.28% | |
| Volatilityi | 24.95% | 24.08% | |
| Sharpe ratioi | 0.12 | 0.03 | |
| Sortino ratioi | 0.16 | 0.04 | |
| Max drawdowni | 47.67% | 58.96% | |
| Current drawdowni | 13.87% | 46.46% | |
| Avg drawdowni | 16.68% | 23.44% | |
| Ulcer Indexi | 20.66% | 30.34% | |
| Max daily dropi | 13.26% | 7.73% | |
| Max wkly dropi | 17.10% | 15.34% |
| Category | BMY | PFE |
|---|---|---|
| Company | BMY | PFE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. | Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.